Medicus Pharma Seeks FDA Priority Approval for SkinJect Treatment

Medicus Pharma Ltd., a biotech company, announced the submission of an application for the FDA Commissioner's National Priority Voucher for SKNJCT-003. This treatment uses a Doxorubicin Microneedle Array for non-invasive basal cell carcinoma therapy. The initiative aligns with FDA's focus on improving drug access and affordability.

The FDA's new voucher system aims to expedite the review process for drugs addressing national health priorities. Medicus's SkinJect could significantly benefit patients, particularly those with Gorlin Syndrome, by reducing surgery dependence. The company is seeking inclusion in the FDA's program to speed up review and approval processes.

Medicus has also been conducting clinical trials to ensure efficacy. Recent expansions include trials in the UK and UAE. The company’s collaboration with the Gorlin Syndrome Alliance further emphasizes its commitment to addressing unmet medical needs.